Summary
Pfizer Inc. (PFE) has filed an 8-K report on August 1, 2023, to announce its financial results for the second quarter ended July 31, 2023. The report primarily serves to furnish a press release detailing these results, which is incorporated by reference as Exhibit 99. Investors should note that this information, as is standard for Item 2.02 filings, is furnished and not deemed "filed" under the Securities Exchange Act of 1934, meaning it does not carry the same liability as formally filed information unless specifically incorporated into other filings. While the 8-K itself does not contain the detailed financial figures, it directs investors to the accompanying press release for the second quarter 2023 performance. This indicates that the key financial metrics, operational updates, and forward-looking statements are contained within that press release. Investors seeking a comprehensive understanding of Pfizer's performance for the reported period should consult Exhibit 99.
Key Highlights
- 1Pfizer Inc. (PFE) announced second quarter 2023 financial results via an 8-K filing on August 1, 2023.
- 2The filing primarily incorporates by reference a press release (Exhibit 99) containing the detailed Q2 2023 financial results.
- 3Investors are directed to the furnished press release for specific financial performance data and operational updates.
- 4The information provided under Item 2.02 is furnished and not "filed" under the Exchange Act, limiting Section 18 liability.
- 5The report includes the Cover Page Interactive Data File in XBRL format as Exhibit 104.